substance p has been researched along with Cardiovascular Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burckhardt, BB; Feickert, M | 1 |
| Bot, I; Kovanen, PT; Shi, GP | 1 |
| Chmielinska, JJ; Komarov, AM; Kramer, JH; Mak, IuT; Tejero-Taldo, MI; Weglicki, WB | 1 |
| Al-Abri, M; Cross, MD; Douglas, NJ; Mackay, TW; Mills, NL; Newby, DE; Riha, R; Vennelle, M | 1 |
| Hörtnagl, H; Kleinberger, G; Lenz, K; Lochs, H; Singer, EA | 1 |
| Weber, KT | 1 |
| Cassidy, MM; Dickens, BF; Kramer, JH; Mak, IT; Philips, TM; Stafford, RE; Weglicki, WB | 1 |
| Chang, Y; Hancock, JC; Hoover, DB; Zhang, L | 1 |
| Tiefenbacher, CP | 1 |
| Black, PH; Garbutt, LD | 1 |
4 review(s) available for substance p and Cardiovascular Diseases
| Article | Year |
|---|---|
Substance P in cardiovascular diseases - A bioanalytical review.
Topics: Animals; Cardiovascular Diseases; Clinical Chemistry Tests; Humans; Saliva; Substance P; Ventricular Remodeling | 2019 |
Role of free radicals and substance P in magnesium deficiency.
Topics: Animals; Cardiovascular Diseases; Free Radicals; Humans; Magnesium Deficiency; Mice; Rats; Substance P | 1996 |
Actions of tachykinins within the heart and their relevance to cardiovascular disease.
Topics: Action Potentials; Afferent Pathways; Animals; Calcitonin Gene-Related Peptide; Cardiovascular Diseases; Cholinergic Fibers; Coronary Vessels; Ganglia; Heart; Hemodynamics; Humans; Myocardial Ischemia; Neurokinin A; Receptors, Tachykinin; Substance P; Tachykinins | 2000 |
Stress, inflammation and cardiovascular disease.
Topics: Acute-Phase Proteins; Adrenal Cortex Hormones; Arteriosclerosis; Brain; Cardiovascular Diseases; Catecholamines; Cytokines; Fibrinolysis; Glucagon; Homocysteine; Human Growth Hormone; Humans; Inflammation; Intercellular Adhesion Molecule-1; Neurons; Renin; Risk Factors; Stress, Psychological; Substance P; Vascular Cell Adhesion Molecule-1 | 2002 |
1 trial(s) available for substance p and Cardiovascular Diseases
| Article | Year |
|---|---|
Continuous positive airway pressure improves vascular function in obstructive sleep apnoea/hypopnoea syndrome: a randomised controlled trial.
Topics: Acetylcholine; Adult; Cardiovascular Diseases; Continuous Positive Airway Pressure; Double-Blind Method; Female; Humans; Hypoxia; Male; Middle Aged; Nitroprusside; Sleep Apnea, Obstructive; Substance P; Vasodilation; Vasodilator Agents | 2008 |
5 other study(ies) available for substance p and Cardiovascular Diseases
| Article | Year |
|---|---|
Reply: The complexity of substance P-mediated mast cell activation.
Topics: Cardiovascular Diseases; Humans; Mast Cells; Substance P | 2017 |
The role of magnesium deficiency in cardiovascular and intestinal inflammation.
Topics: Animals; Cardiovascular Diseases; Humans; Intestinal Mucosa; Intestines; Magnesium Deficiency; Receptors, Neurokinin-1; Substance P | 2010 |
Substance P is markedly increased in plasma of patients with hepatic coma.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiac Output; Cardiovascular Diseases; Child; Epinephrine; Female; Heart Rate; Hemodynamics; Hepatic Encephalopathy; Humans; Liver; Male; Middle Aged; Norepinephrine; Substance P; Vascular Resistance | 1984 |
White mineral and substance P.
Topics: Animals; Cardiovascular Diseases; Free Radicals; Humans; Magnesium Deficiency; Mice; Rats; Substance P | 1996 |
Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction?
Topics: Animals; Arginine; Biopterins; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Vessels; Dogs; Endothelium, Vascular; Enzyme Inhibitors; Histamine; Humans; Hypercholesterolemia; In Vitro Techniques; Infusions, Intra-Arterial; Ionophores; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; omega-N-Methylarginine; Pteridines; Pterins; Reactive Oxygen Species; Species Specificity; Substance P; Swine; Vasoconstrictor Agents; Vasodilator Agents | 2001 |